PTGX
Protagonist Therapeutics Inc

3,359
Mkt Cap
$5.45B
Volume
706,162.00
52W High
$96.54
52W Low
$35.95
PE Ratio
137.51
PTGX Fundamentals
Price
$88.39
Prev Close
$87.10
Open
$87.50
50D MA
$84.73
Beta
0.45
Avg. Volume
870,278.30
EPS (Annual)
$4.23
P/B
8.43
Rev/Employee
$3.45M
$2,103.95
Loading...
Loading...
News
all
press releases
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00
TD Cowen upped their price target on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Thursday...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays
Barclays raised their price objective on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the company an "overweight" rating in a research note on Thursday...
MarketBeat·10h ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00
Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a "market outperform" rating in a report on Thursday...
MarketBeat·10h ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the...
MarketBeat·1d ago
News Placeholder
Lewis Williams Sells 18,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director Lewis Williams sold 18,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average...
MarketBeat·8d ago
News Placeholder
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen ratings firms that are presently covering the firm, Marketbeat...
MarketBeat·8d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams Sells 18,000 Shares
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director Lewis Williams sold 18,000 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at...
MarketBeat·8d ago
News Placeholder
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
Key PointsA director for Protagonist Therapeutics sold 20,000 shares for a transaction value of approximately $1.7 million on Feb. 6, 2026...
Nasdaq News: Markets·11d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Stake Boosted by Public Sector Pension Investment Board
Public Sector Pension Investment Board boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.0% during the 3rd quarter, according to the company in its most...
MarketBeat·12d ago
News Placeholder
Protagonist Therapeutics (PTGX) to Release Earnings on Friday
Protagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q4 2025 earnings before the market opens on Friday, February 20. (View Earnings Report at...
MarketBeat·14d ago
<
1
2
...
>

Latest PTGX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.